Gsk (GSK) Total Non-Current Liabilities (2009 - 2026)

Gsk (GSK) has 18 years of Total Non-Current Liabilities data on file, last reported at -$30.9 billion in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 5.57% year-over-year to -$30.9 billion; the trailing twelve-month figure through Jun 2026 stood at -$30.9 billion (up 5.57% YoY), and the FY2025 full-year result was -$31.6 billion, changed 0.23% from the prior year.
• Total Non-Current Liabilities was -$30.9 billion for Q2 2026 at Gsk, roughly flat from -$31.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of -$17.6 billion in Q1 2022 to a low of -$36.1 billion in Q3 2022.
• A 5-year average of -$31.4 billion and a median of -$31.8 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 65.23% in 2022 and sank 83.18% in 2023, its largest moves.
• Gsk's Total Non-Current Liabilities stood at -$32.0 billion in 2022, then climbed by 2.33% to -$31.2 billion in 2023, then slipped by 1.51% to -$31.7 billion in 2024, then gained by 0.18% to -$31.6 billion in 2025, then climbed by 2.29% to -$30.9 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were -$30.9 billion in Q2 2026, -$31.0 billion in Q1 2026, and -$31.6 billion in Q4 2025.